biostudies-literatureUnknown18(1)Fain O<h4>Background</h4>Hereditary angioedema (HAE) is associated with a heavy burden of illness.<h4>Objective</h4>To evaluate use of lanadelumab in a French Authorization for Temporary Use (ATU) program.<h4>Methods</h4>ATU requests were made between October 12, 2018, and March 13, 2019; patients were followed through September 23, 2019. At entry, patients received lanadelumab 300 mg every 2 weeks. HAE attack characteristics were evaluated at day (D) 0 and months (M) 3 and 6. Patients completed the Angioedema Quality of Life (AE-QoL) questionnaire at initiation and monthly and the Angioedema Activity Score questionnaire daily in 28 day cycles (AAS28).<h4>Results</h4>In total, 77 patients received ≥ 1 lanadelumab dose; 69 had ≥ 1 quarterly follow-up visit (analyzed population). Mean (standard deAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology30https://www.ebi.ac.uk/biostudies/studies/S-EPMC8976389biostudies-literatureLong-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.PMC8976389Boudjemia KLaunay DWeiss LAubineau MFain ODu-Thanh AGobert DInhaber NBoccon-Gibod IBouillet LSobel AfalseLong-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.<h4>Background</h4>Hereditary angioedema (HAE) is associated with a heavy burden of illness.<h4>Objective</h4>To evaluate use of lanadelumab in a French Authorization for Temporary Use (ATU) program.<h4>Methods</h4>ATU requests were made between October 12, 2018, and March 13, 2019; patients were followed through September 23, 2019. At entry, patients received lanadelumab 300 mg every 2 weeks. HAE attack characteristics were evaluated at day (D) 0 and months (M) 3 and 6. Patients completed the Angioedema Quality of Life (AE-QoL) questionnaire at initiation and monthly and the Angioedema Activity Score questionnaire daily in 28 day cycles (AAS28).<h4>Results</h4>In total, 77 patients received ≥ 1 lanadelumab dose; 69 had ≥ 1 quarterly follow-up visit (analyzed population). Mean (standard de2022-01-01T00:00:00Z2022 Apr2025-06-01T02:44:09.335Z2025-06-01T02:44:09.335ZS-EPMC89763893536523410.1186/s13223-022-00664-4